CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 793 enrolled
Drug / intervention
LIPO-202 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02398188
NCT02398188Phase 3Completed
CompareCT.gov

A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat in Non-Obese Subjects

Evofem Inc.·interventional·Posted Mar 25, 2015·Updated Jan 7, 2019

In Brief

A Phase 3 clinical trial evaluating LIPO-202 and Placebo for Central Abdominal Bulging. Completed, enrolled 793 participants across 35 sites.

Detailed Summary

This is a multi-center, randomized, double-blinded, placebo-controlled study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCentral Abdominal Bulging
CountriesUnited States
CollaboratorsNeothetics, Inc

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 25, 2015
Enrollment StartApr 9, 2015
Primary CompletionOct 29, 2015
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 11.3 years ago

Interventions

LIPO-202drug

Placebodrug